Rachit Kumar, MD

Articles by Rachit Kumar, MD

Genetic Data May Inform Personalized Radiotherapy Strategies for Cancer Care

April 14th 2025

Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

ByRachit Kumar, MD,Michael J. Pishvaian, MD, PhD,Nina D. Wagner-Johnston, MD,Valerie Lee, MD,Armine K. Smith, MD,Pouneh Razavi, MD,Curtiland Deville Jr., MD

April 7th 2025

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.

Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers

ByRachit Kumar, MD

April 6th 2025

Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.

Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.

Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer

ByRachit Kumar, MD

April 3rd 2025

Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.

Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.

Optimizing Opportunities to Deliver Personalized Radiation Oncology Care

ByRachit Kumar, MD,Curtiland Deville Jr., MD

March 30th 2025

Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.

ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer

ByWilliam Small, Jr, MD,John P. Hayes, MD,W. Warren Suh, MD, MPH,May Abdel-Wahab, MD, PhD,Ross A. Abrams, MD,Nilofer Azad, MD,Prajnan Das, MD, MS, MPH,Jadranka Dragovic, MD,Karyn A. Goodman, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Percy Lee, MD,Timothy M. Pawlik, MD,Joseph M. Herman, MD, MSc

July 15th 2016

These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.

ACR Appropriateness Criteria® Resectable Stomach Cancer

ByParima Daroui, MD, PhD,Salma K. Jabbour, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Karyn A. Goodman, MD,Theodore S. Hong, MD,William E. Jones III, MD,Harmeet Kaur, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Timothy M. Pawlik, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD, MPH

August 15th 2015

For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection.

ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation

ByKaryn A. Goodman, MD,Sarah A. Milgrom, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Theodore S. Hong, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Miguel Rodriguez-Bigas, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD

October 15th 2014

The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.